ArticleNeoplasia (New York, N.Y.)2026
Glioblastoma recurrence: An NGS-centered seed-soil framework.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrence of IDH-wild-type glioblastoma (GBM) remains the major obstacle to improving patient survival. Current recurrence models emphasize tumor-intrinsic mechanisms, including therapeutic resistance, cellular plasticity, and clonal evolution, but do not fully explain how residual tumor cells reconstruct recurrent disease after surgery. Here, we propose an NGS-centered seed-soil framework that considers surgical resection as the starting point of recurrence evolution: residual NEU/OPC/NPC-like tumor cells represent potential recurrence "seed", the postsurgical brain constitutes a dynamically remodeled "soil", and neuron-glioma synapse (NGS) provides a potential interface between residual tumor cells and neurons of this environment. At the recurrence endpoint, recurrent GBM exhibits enhanced neuronal and NGS-associated characteristics, providing an observable phenotype with which this framework can be evaluated. We then examine the potential processes linking these two states, including therapy-associated NGS remodeling, NGS-associated network reconstruction, and neuronal-like migration, which may contribute to the development of local and distant recurrence. Throughout, established observations are distinguished from hypothesis-driven interpretations and untested predictions. Finally, we discuss critical experimental requirements, including longitudinal post-resection models and NGS-specific perturbation, as well as emerging translational opportunities such as neuromodulation and perioperative intervention. This framework shifts the perspective on GBM recurrence from residual tumor-cell survival alone toward dynamic interactions between residual tumor cells and the postsurgical neural environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.